Broncho-Vaxom
Sponsors
OM Pharma SA, Vifor Pharma, University of North Carolina, Chapel Hill, Fang Deng, Franciscus Gasthuis
Conditions
AsthmaAtopic DermatitisLRTINephrotic Syndrome in ChildrenPrematureRecurrent wheezingWheezing
Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
CompletedNCT04129931
Start: 2019-12-19End: 2025-03-19Updated: 2026-04-01
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
TerminatedNCT05222516
Start: 2021-12-20End: 2023-07-13Updated: 2023-08-08
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Active, not recruitingCTIS2024-511083-90-00
Start: 2024-10-03Target: 85Updated: 2025-10-17
Phase 3
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
CompletedNCT03047954
Start: 2003-07-31End: 2006-12-31Updated: 2017-02-09
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
RecruitingNCT05063149
Start: 2022-01-18End: 2026-12-31Target: 500Updated: 2024-08-22